The 1st September 2025 marks the official start of the 2025–2026 epidemiological year for the id.DRIVE studies, kicking off another year dedicated to tracking respiratory infectious diseases and advancing collaborative science in Europe.
Months of preparation and dedication have led to the activation of 31 hospitals, representing 13 Study Contributors,in France, Germany, Italy, Spain and United Kingdom.
Research focus for 2025–2026
This year, the partnership is conducting three major studies:
- Surveillance of multiple respiratory viruses in adults hospitalized with Severe Acute Respiratory Infection (SARI).
- Effectiveness of COVID-19 vaccines in adults hospitalized with SARI.
- Effectiveness of RSV vaccines in older adults hospitalized with SARI.
The updated study protocols have recently been approved, and the latest versions are now available on the https://iddrive.eu/study-documents/.
A thriving study network
The id.DRIVE partnership builds on the foundation laid by the DRIVE Project that started eight years ago. The study network continues to grow, supported by the collaboration between the id.DRIVE partners, 13 European research sites, and dedicated teams.
“Thanks to the id.DRIVE team and our collaborators across Europe for making this possible once again,” said the Principal Investigator of the id.DRIVE studies, Kaatje Bollaerts (P95). “It is inspiring to see how our network continues to expand and strengthen year after year.”
The partnership extends its best wishes to all study teams and collaborators for a successful 2025–2026 epidemiological year. Stay tuned for updates through our website.
